Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Abscess | D000038 | EFO_0003030 | — | — | — | 1 | 1 | — | 2 |
Liver abscess | D008100 | — | K75.0 | — | — | — | 1 | — | 1 |
Pyogenic liver abscess | D046290 | EFO_1001836 | — | — | — | — | 1 | — | 1 |
Chronic bronchitis | D029481 | — | J42 | — | — | — | 1 | — | 1 |
Bronchitis | D001991 | — | J40 | — | — | — | 1 | — | 1 |
Acute disease | D000208 | — | — | — | — | — | 1 | — | 1 |
Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | 1 | — | 1 |
Bacterial infections | D001424 | — | A49 | — | — | — | 1 | — | 1 |
Rhinosinusitis | D000096825 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | — | 1 |
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | 1 | — | — | 1 |
Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | — | 1 | — | — | 1 |
Coronavirus | D017934 | — | — | — | — | 1 | — | — | 1 |
Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 1 | — | — | 1 |
Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | — | 1 |
Diabetic foot | D017719 | EFO_1001459 | — | — | — | 1 | — | — | 1 |
Communicable diseases | D003141 | — | — | — | — | 1 | — | — | 1 |
Wound infection | D014946 | — | — | — | — | 1 | — | — | 1 |
Drug common name | Etrolizumab |
INN | etrolizumab |
Description | Etrolizumab (humanized mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1743015 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | I2A72G2V3J (ChemIDplus, GSRS) |